On March 2, 2020, Gilead and Forty Seven announced that Forty Seven, Gilead and Purchaser had signed a definitive merger agreement pursuant to which a tender offer would be made. This press release features multimedia. This press release features multimedia. The transaction, which values Forty Seven at approximately $4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter of 2020, subject to regulatory approvals and other customary closing conditions. Drugmaker Gilead Sciences Inc has approached cancer therapy company Forty Seven Inc with a takeover offer, Bloomberg News reported on Thursday, citing people familiar with the matter. On April 7, 2020, Gilead successfully completed the tender offer for all outstanding shares of common stock of Forty Seven and accepted for payment … In March 2020, the company announced it would acquire Forty Seven Inc. for $95.50 a share ($4.9 billion in total). On April 7, 2020, Gilead completed acquisition of Forty Seven, Inc. for "$95.50 per share, net to the seller in cash, without interest, or approximately $4.9 billion in the aggregate."

Gilead Sciences (NASDAQ:GILD) is reportedly in buyout, or possible licensing, talks with the clinical-stage cancer company Forty Seven (NASDAQ:FTSV), according to Bloomberg. Gilead’s accepted bid values Forty Seven at $95 a share. This press release features multimedia. Gilead Sciences Inc said on Monday it would buy Forty Seven Inc for $4.9 billion in cash, adding an experimental treatment that targets blood cancer to its portfolio of oncology drugs. Gilead Sciences (NASDAQ:GILD) is reportedly in buyout, or possible licensing, talks with the clinical-stage cancer company Forty Seven (NASDAQ:FTSV), according to Bloomberg. Gilead Sciences has agreed to acquire Forty Seven for $4.9 billion cash, in a deal intended to boost the buyer’s immuno-oncology R&D pipeline—anchored by Forty Seven… The agreements are part of a years-long effort by Gilead to develop a … This deal follows Gilead's $4.9 billion takeout of Forty Seven and a collaboration with Arcus Biosciences that saw Gilead pay $175 million cash and buy $200 million worth of shares. On March 2, 2020, Gilead and Forty Seven announced that Forty Seven, Gilead and Purchaser had signed a definitive merger agreement pursuant to which a tender offer would be made. For most of its time on public markets, Forty Seven has traded below $20, dipping as low … The transaction, which values Forty Seven at approximately $4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter of 2020, subject to regulatory approvals and other customary closing conditions.

Gilead has explored a number of options, including a partnership, said the people, asking not to be identified as the matter is private.

Gilead Sciences Inc said on Monday it would buy Forty Seven Inc for $4.9 billion in cash, adding an experimental treatment that targets blood cancer to its portfolio of oncology drugs. The transaction, which values Forty Seven at approximately $4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter of 2020, subject to regulatory approvals and other customary closing conditions. Forty Seven surges on confirmation that it and its flagship cancer-fighting treatment are being bought by Gilead Sciences for $95.50 a share in cash. Gilead has explored a number of options, including a partnership, said the people, asking not to be identified as the matter is private.